TechFlow news, September 22: According to a Hong Kong Stock Exchange announcement, Hua Jian Medical and Transcenta signed a $1.5 billion strategic cooperation agreement, pioneering the tokenization of global innovative drug intellectual property rights. Under the agreement, Transcenta will consolidate six core innovative drug pipeline assets (TST003, TST005, TST786, TST105, TST106, TST013) into its U.S. subsidiary and tokenize these assets through ETHK, Hua Jian Medical's global RWA exchange for innovative drug intellectual property rights. This collaboration establishes a new model integrating technology and finance within the biopharmaceutical industry, marking the first time high-value innovative drug intellectual property assets are launched in capital markets as RWAs.
Risk Disclosure: This website's content is not investment advice and offers no trading guidance or related services. Per regulations from the PBOC and other authorities, users must be aware of virtual currency risks. Contact us / support@techflowpost.com ICP License: 琼ICP备2022009338号
